According to multiple media reports, Verona Pharma’s investigational COPD therapy ensifentrine missed its primary endpoint in a phase 2 trial.

The dual PDE3/PDE4 inhibitor failed to beat placebo on a measure of lung function.

Investigators enrolled 79 COPD patients and randomized them to receive ensifentrine or placebo for three days on top of Boehringer Ingelheim’s Stiolto Respimat. About two-fifths of participants were also taking inhaled corticosteroids.